GENENTECH, INC for GENENTECH INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Patent Reform, CPT - H.R. 243 Patent Lawsuit Reform Act of 2011; H.R. 1249 Leahy-Smith America Invents Act S.23-America Invents Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| EVAN MORRIS | VP |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
Budget/Appropriations: FY12 appropriations process, including H.R. 2112 and various continuing resolutions: FDA funding issues and drug approval/review oversight process.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asscoc. Director of Government Affairs |
| DARIN GARDNER | Director of Government Affairs |
| ELI KOGAN | Assoc. Director of Government Affairs |
| EVAN MORRIS | VP of Government Affairs |
Food Industry (safety, labeling, etc.) FOO
Monitor and report on Food safety and supply chain issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| ELI KOGAN | Assoc. Director |
| EVAN MORRIS | VP |
Trade (domestic/foreign) TRD
Monitor issues related to export rules and regulations, international patent issues, WTO matters, the Trans-Pacific partnership, and other international issues impacting biotech and pharmaceuticals
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
| EVAN MORRIS | VP |
Health Issues HCR
Implement of H.R.: Miedicare Prescription Drug and Modernization Act of 2003: Issures relating to PDUFA stimulus, issues relation to comparative effectivness and CMS coverage of FDA approved therapies, issues related to the PPS rule involving stroke guidelines. Implementation of the follow-on bilogice provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"HR 1/1473 helath care funding; FY12 Labor HHS Appropriations legislation, advocate for approval of Avasitn for late stage breast cancer treatment, Implementation of the Affordable Care of Act of 2010, Advocacy related to ensuring access to necessary medicines, Avastin PDUFA Reauthorization, issues related to pandemic preparedness and mascular degeneration, FDA approval and enforcement issues, 340B payment and implementation issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director of Government Affairs |
| DARIN GARDNER | Director of Government Affairs |
| ELI KOGAN | Assoc. Director of Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs |
Medicare/Medicaid MMM
Medicare Issues; Monitor implementation of Medicare Pharmaceutical converage and reimbursement provisions of the Affordable Care Act, Medicare coverage and payment of Part B drugs and biologicals. Support for H.R 452 "Medicare Decision Accountability Act of 2011 and S.668 "Health Care Bureaucrats Elmination Act".
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director of Government Affairs |
| DARIN GARDNER | Assoc. Director of Government Affairs |
| EVAN MORRIS | VP of Government Affairs |
| KATHERINE RAAB | Director of Government Affairs |
Pharmacy PHA
Monitor Drug Safety and pedigree legislation, advocacy related to ensuring access to necessary medicines, payment policies for prescription drugs, Prescription Drug User Free Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
| EVAN MORRIS New | VP |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.